pemafibrate
Kowa Pharmaceuticals
[]
tg-lowering with pemafibrate did not reduce cvd in high risk patients. [ ] alternative pathways [ ], including apociii and angptl3 inhibition, may help to clarify these issues. two targets with weak genetic evidence to affect cvd. go angptl4! #aha2022
Life science entrepreneur, CEO and founder of @Lipigon_Pharma $LPGO traded at Nasdaq FNGM